Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

June 30, 2013

Study Completion Date

October 31, 2013

Conditions
Ovarian CancerPeritoneal CancerFallopian Tube Cancer
Interventions
DRUG

intravenous docetaxel with intraperitoneal oxaliplatin

IV docetaxel 75 mg/m2 over 1 hour on day #1 followed by intraperitoneal oxaliplatin escalating from 50 mg/m2 on day #2. Cycles of treatment will be repeated every 3 weeks until disease progression or intolerable toxicity occurs.

DRUG

intravenous oxaliplatin with intraperitoneal docetaxel

IV oxaliplatin 75 mg/m2 over 1 hour on day #1 followed by intraperitoneal docetaxel escalating from 50 mg/m2 on day #2. Cycles of treatment will be repeated every 3 weeks until disease progression or intolerable toxicity occurs.

Trial Locations (1)

15213

Magee-Womens Hospital of UPMC, Pittsburgh

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

University of Pittsburgh

OTHER